Does Indiana Medicaid Cover Zepbound or Wegovy? The Four PA Routes

Not for weight loss in adults. As of November 2026, Indiana Medicaid excludes “any agent used to promote weight loss” under state rule, but Zepbound is a preferred drug for moderate to severe sleep apnea and Wegovy is covered for heart-risk reduction or the liver disease MASH, each with prior authorization.^[1][2] Members under 21 can also be approved for weight-loss drugs through the federal EPSDT benefit.^[3]

Does Indiana Medicaid cover Zepbound or Wegovy for weight loss?

Not for adults. The first page of Indiana’s drug list repeats the state rule, 405 IAC 5-24, which removes appetite suppressants and every other drug taken to lose weight from the benefit.^[1] The criteria for both drugs carry the same warning in their headings: “not covered exclusively for weight loss.”^[2] This is legal under federal law, since weight-loss agents are one of the short list of drug uses a state Medicaid program may exclude.^[7] Our explainer on why Medicaid treats Ozempic and Wegovy differently covers the federal side.

The plan you are in does not change a drug’s status. Indiana runs one statewide list that applies to fee-for-service claims and to every managed care plan.^[1] Prior authorization is split, though. Fee-for-service requests go to Optum Rx at 855-577-6317, or by fax to 855-577-6384, while each managed care plan sets and publishes its own prior authorization criteria and answers questions about them.^[1][6] The criteria on this page are the Optum Rx ones, so a managed care member should ask the plan for its version. Switching plans will not open a weight-loss route for adults, because the state rule covers the whole program.^[1]

When does Indiana Medicaid pay for a GLP-1?

Two quirks stand out. Zepbound is the preferred tirzepatide, while Mounjaro, the same drug sold for diabetes, is non-preferred.^[1] Yet Zepbound’s criteria exclude anyone with diabetes, so a person with type 2 diabetes who wants tirzepatide is pushed to the non-preferred Mounjaro request instead.^[2] The July and August 2026 rounds of drug board changes did not alter the GLP-1 class.^[5][6] In October the board approved revised GLP-1 prior authorization criteria for requests submitted from January 1, 2027, with no change to which GLP-1 drugs are preferred; the revised criteria were not yet posted when we checked on November 6, 2026.^[15]

What does Indiana require for Zepbound and sleep apnea?

An adult with obesity and moderate to severe obstructive sleep apnea, with 15 or more breathing pauses or drops an hour on a sleep study (the apnea-hypopnea index, or AHI).^[2] The sleep test can be a lab study or a home test, but a sleep medicine-certified physician must have read it, and it must be from the past year.^[2] The BMI must be at least 30, recorded within the past three months, which matches the label’s limit to adults with obesity.^[2][9]

Indiana does not demand a CPAP trial first. It uses CPAP the other way round: someone whose qualifying test is older can still be approved by showing they use a positive airway pressure machine at least four hours a night on at least 70% of nights.^[2] The prescriber must also confirm that the member has no diabetes, an A1c under 6.5%, and no mostly central or mixed sleep apnea.^[2]

Approval lasts a year. The first renewal needs a repeat sleep study or device data showing a lower AHI, and every renewal needs a weight loss of at least 5% from the starting weight.^[2] That second rule is stricter than it looks, because it applies even when breathing has improved. Our guide to Zepbound for sleep apnea explains the trials behind the indication.

Will Indiana Medicaid cover Wegovy for heart disease?

Yes, with prior authorization, but the bar is higher than the label. The label takes in any adult with existing heart disease who carries excess weight, whether obesity or overweight.^[10] Indiana wants the member to be 45 or older with a BMI of 27 or higher, plus one of three events: a past heart attack, a past stroke, or symptomatic peripheral artery disease shown by amputation, a bypass or stent procedure, or leg pain with an ankle-brachial index below 0.85.^[2]

Those rules track the SELECT trial almost exactly. SELECT enrolled people 45 and older with existing heart disease, a BMI from 27 up and no diabetes history, and found a 20% lower rate of heart death, heart attack or stroke with semaglutide (hazard ratio 0.80).^[11] Indiana adds the trial’s diabetes exclusion as a rule, and asks that the member already take a beta-blocker or a blood pressure drug from the RAS group plus a cholesterol drug, unless the prescriber explains why not.^[2] The Wegovy tablet has the same heart criteria plus a written reason for choosing it over the injection.^[2]

Does Indiana Medicaid cover a GLP-1 for fatty liver?

Yes, through two drugs. Wegovy is approved for MASH in adults when a biopsy from the past two years shows F2 to F3 fibrosis without cirrhosis, or a Fibroscan from the past six months shows a liver stiffness of at least 9.1 kPa with a fat score (CAP) of at least 280.^[2] An endocrinologist, gastroenterologist or hepatologist must prescribe it or be consulted.^[2] Someone with type 2 diabetes qualifies only after 18 months on Ozempic at 2 mg a week without enough improvement.^[2]

Ozempic, the preferred semaglutide, has a broader liver route of its own. Its criteria accept MASH with F1 to F3 fibrosis, or the milder fatty liver disease MASLD, with lower Fibroscan cutoffs, and they do not require diabetes.^[2] Ozempic’s FDA label lists only uses in type 2 diabetes, so this is a coverage choice by the state.^[14] Our review of GLP-1s and MASH explains what the evidence shows.

Can a teenager on Indiana Medicaid get Wegovy?

Possibly. Federal law requires Medicaid to pay for necessary treatment for children and young adults under 21 found through EPSDT screening, whether or not the state plan covers it.^[8] Indiana’s prior authorization contractor, Acentra Health, says obesity drugs are not a benefit outside EPSDT and names Wegovy, Saxenda and Imcivree as the drugs most often requested.^[3]

The request needs a diagnosis of severe obesity with other health conditions, records of nutrition counseling or a weight-loss program, and a list of drugs and treatments already tried.^[3] Acentra reviews only the first request; renewals for the same drug go to Optum Rx.^[3] Wegovy’s label covers obesity from age 12.^[10] Our page on GLP-1 drugs in teenagers covers the trial results.

How do you appeal a denial in Indiana?

First read the reason. A missing sleep study, BMI or specialist note can often be fixed by resubmitting, and a request based only on adult obesity has no route to win.^[1] The deadlines depend on how you are enrolled. Fee-for-service members must have a fair hearing request received within 33 calendar days of the notice or the action’s effective date.^[4] Managed care members first finish their plan’s appeal, then have 120 calendar days to ask for a state fair hearing.^[4]

The 33-day window is short, so file early and keep proof of the date. Our walkthrough of prior authorization and appeals covers what to send, and the Indiana state page summarizes the Medicaid facts.

What can you do if Indiana Medicaid will not pay?

Cash is the main option, and the manufacturer savings card does not help: Lilly’s terms exclude anyone enrolled in Medicaid.^[12] In the prices we track, Novo Nordisk charges $349 a month for most Wegovy pen doses, and Lilly charges $299 for the starting Zepbound KwikPen dose, $399 at 5 mg and $449 at higher doses when refills stay on schedule.^[12][13] Check each program’s terms on government coverage before you enroll. Our comparison of low-cost GLP-1 routes for people paying cash sets them side by side.